Representative Julie Johnson (D-Texas) disclosed on January 15th that she sold between $1,001 and $15,000 worth of UnitedHealth Group shares on December 18th through her Chase Brokerage Account (3935). This transaction adds to a series of similar sales across multiple blue-chip names on the same date, but the sale of UnitedHealth stock is particularly notable given the company’s prominence in the health-insurance sector and its large market capitalization.

In its third-quarter report released October 28th, UnitedHealth Group reported earnings per share of $2.92, surpassing analyst expectations of $2.87 by $0.05. Revenue reached $113.16 billion, in line with projections, and represented a 12.2% year-over-year increase. The company delivered a return on equity of 19.23% and a net margin of 4.04%. Equity analysts anticipate full-year earnings of approximately $29.54 per share, underscoring continued profitability momentum across both UnitedHealthcare benefits and Optum services.

UnitedHealth Group declared a quarterly dividend of $2.21 per share, payable December 16th, to shareholders of record December 8th. This dividend translates to an annualized payout of $8.84 per share and a yield near 2.7%. With a payout ratio of 46.14%, management has balanced returning capital to shareholders while retaining funds to support growth initiatives in care delivery and technology.

Institutional investors collectively hold 87.86% of UnitedHealth Group’s outstanding shares. In the third quarter, North Capital Inc. increased its stake by 16.2% to 194 shares; Sunflower Bank N.A. added 1.5% more to reach 1,916 shares; Axis Wealth Partners lifted its position by 1.7% to 1,631 shares; Abound Wealth Management grew its holding by 13.5% to 244 shares; and Cooper Financial Group modestly increased its stake by 0.7% to 4,338 shares. These incremental adjustments reflect ongoing institutional confidence in UnitedHealth Group’s long-term growth trajectory.